XXXX -Supported Hip Implants: Short Term Clinical Results.

@entity1 @entity1496 @entity137 @entity625 @entity4279 @entity281 @entity572 @entity86 @entity702 @entity1851
UNASSIGNED: We developed a new @entity4279 coating technology for @entity702 hip implants and performed a clinical trial to assess its usefulness in suppressing @entity86 . Results indicate that @entity1496 -supported @entity702 has favorable antibacterial activity, biocompatibility, and no @entity137 . Thirty joints in 28 @entity1 were treated using @entity1496 -supported implants. Fourteen joints were revision @entity572 ( @entity572 ) after @entity281 , 13 were primary @entity572 for immunosuppressive conditions or @entity625 , and 3 were conversions from hemiarthroplasty to @entity572 for immunosuppressive conditions. Two examinations were conducted sequentially until final follow-up: white blood cell (WBC) and @entity1851 ( @entity1851 ) were measured pre- and postoperatively and thyroid hormone levels in the blood were examined. The mean follow-up period was 33 months (14-78). There were no signs of @entity281 in any @entity1 at the last follow-up. WBC and @entity1851 levels returned to normal within several weeks. No abnormalities of thyroid gland function were detected. Loosening of the implants did not occur in any @entity1 . Excellent bone ingrowth and ongrowth were found around prostheses. No @entity137 or adverse effects were detected. These results suggest that @entity1496 -supported @entity572 implants can be highly effective in preventing and treating @entity86 .
